Cardiac Surgical ProceduresNCT04639089
The Effect of Platelet Rich Pasma on Strenal Healing Post Median Strenotomy in Patients Undergoing Open Heart Surgery
A study testing platlet rich plasma on sternal healing post median sternotomy in people with Cardiac Surgical Procedures, run by Dr. Hamdy Singab at 1 site in Egypt.
Trial summary
Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small volume of plasma. Because it is an autogenous preparation, PRP is inherently safe and therefore free from concerns over transmissible diseases such as HIV and hepatitis. Read more about this study
- Who is it for?
- Ages 70 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiac Surgical Procedures
- What is being tested?
- platlet rich plasma on sternal healing post median sternotomy
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 1 siteEgypt
- Study dates
- 14 Aug 2020to 15 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 to 90 years
- All sexes
- Healthy volunteers accepted
- Older adult
Who may be able to join
- Patients with one of which
- patients will under go open heart surgery with BMI >30 or
- diabetic patients
- patients with history of chest wall radiotherapy exposure or
- bilateral internal mammary artery harvesting .
- age > 70 years old
Who cannot join
- patient with history of open heart surgery 2- patients with preoperative HB level <11 3-All emergency and urgency cardiothoracic surgery
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Hamdy Singab
Cairo, 11517
hamdy singab, 01001008859, hamdi_singab@hotmail.com
About this study
Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small volume of plasma.
Because it is an autogenous preparation, PRP is inherently safe and therefore free from concerns over transmissible diseases such as HIV and hepatitis.
Its power of regeneration already proved by orthopedics and dentists in their trials to regenerate cartilages .We will use it to know its ability to enhance healing of sternum in vulnerable patients to sternal dehiscence after open heart surgery .
Read the detailed description
- INTRODUCTION Successful healing of the sternum after open heart surgery is a complicated phenomenon because of the natural body ability often fails to efficiently repaired of the sternum in patients after open cardiac surgery (Everts 2006). Recent evidence based data suggested new modalities to increase the quality and accerelate sternal healing in high risk patients after open heart surgery vulnerable for early sternal dehiscence (Liu 2002) . PRP considers as an attractive alternative option in that manner. Marx and associates demonstrated the positive influence of PRP on bone regeneration and healing since 1998 (Marx 1998 ) . Autologous PRP carries minimal risk of infectious diseases transmission, immunologic reactions, and rejection. PRP with concentrations 4 to 5 folds of the normal average platelet (1,100,000 platelets/μl ) proved to have a remarkable increase in bone mineral density and regeneration . the market for PRP grows from $45 million in 2009 to more than $120 million by 2016 (Dawood 2018 ). Multiple factors affect the PRP efficacy in sternal bone healing and regeneration process. Platelet preparation before surgical application is an area of concern with PRP. For this issue, an appropriate anticoagulant must be used to prevent the early spontaneous activation of the platelets (Kassolis 2000 ). Several anticoagulants have been employed for PRP preparation including heparin, citrate, acid-citrate-dextrose solution A or anticoagulant citrate dextrose-A ,citrate-phos phate-dextrose ,citrate-theophylline-adenosine- dipyrimadole and ethylene diamine tetra- acetic acid moreover, several manual or automated systems have been designed for preparing PRP including clinical laboratory methods and kits (Carlson 2002). PRP produced by single- or double-step centrifugation technology via platelet-pheresis (autologous selective filtration )and the cell separators,However, these methods are rarely used nowadays, due to several factors including high cost, large volume of peripheral blood should be harvested from the patients, and potentially damage to the platelet (Dhurat 2014) . Commercially available PRP kits and devices differ in ease of use, one or two step centrifugation protocols, centrifugation speed, final PRP volume, platelet count and activation, platelet and growth factor concentrations, and final RBCs' and WBCs' count.Nevertheless, the cost of the commercial kits for PRP processing is still a challenge (Trebinjac 2020) .
- AIM/ OBJECTIVES : To study the Effect of platlet rich plasma on sternal healing post median sternotomy in Patients undergoing open heart surgery
- METHODOLOGY:
- Type of Study: prospective clinical trial propensity matched comparative study
- Study Setting: Patients refered to our Cardiothoracic department, Faculty of medicine, Ain Shams University and ain shams specialized hospital to perform open heart surgery who fulfill our inclusion charateria.
- Study Period: It will be performed between march 2020 and january2022
- Study Population:
- Inclusion Criteria: Patients with one of which
- patients will under go open heart surgery with BMI >30 or
- diabetic patients
- patients with history of chest wall radiotherapy exposure or
- bilateral internal mammary artery harvesting .
- age > 70 years old -Exclusion Criteria: <!-- -->
- patient with history of open heart surgery
- patients with preoperative HB level <11
- All emergency and urgency cardiothoracic surgery
- Sampling Method: prospective clinical trials propensity matched comparative study.
- Sample Size: 50 patients
- Ethical Considerations: All the patients will sign an informed consent for operation and for being involved in the research and follow up process .
- Study Tools: platlets rich plasma
- Preparation technique : ultra centrifuge technique
- Study Procedures:
Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA
Intraoperative :
We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.
post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery sternal stability and absence of dehiscence will be primary out come measure
Secondary end point :
Severe form of sternal deheiscence After 3months: stability of sternum will be assessed By CT chest with 3D bone reconstruction and the value of bone density as aconfirmatory test
- Statistical Analysis:using the arithmetic mean, standard deviation using hypothesis student's "t" tests for quantitative data analysis, while qualitative data (ordinal, categorical) will be analyzed using The chi-square test (x2) (Fisher's Exact Test). For all statistical comparisons, a P value of <0.05 will be considered significant and a P value of <0.01 will be considered highly significant.
- Statistical Package:Data will be statistically analyzed using statistical package of social science (SPSS)
- Conditions
- Cardiac Surgical Procedures
- Being tested
- platlet rich plasma on sternal healing post median sternotomy
- Keywords
- Cardiac Surgical Procedures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
platlet rich plasma on sternal healing post median sternotomyDrug
Also called PRP
Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA
Intraoperative :
We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.
post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery
| Study group | Role | What they receive |
|---|---|---|
| We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure | Experimental | We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure Receives: Drug: platlet rich plasma on sternal healing post median sternotomy |
| We will apply 10cm saline on the sternal edge before sternal closure | Placebo comparator | We will apply 10cm saline on the sternal edge before sternal closure Receives: Drug: platlet rich plasma on sternal healing post median sternotomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
sternal stability and absence of dehiscence
Radiographic strenal healing score information was collected from 50 patients during clinical follow-up determined by CT chest 3D axial slices analysis at five locations ( manubrium, top of aortic arch, main pulmonary artery , aortic root and aortopulmonary window) using 5 - points quantitative scale 0:minimal healing
- no signs of healing
- mild healing
- moderate healing
- complete healing
Measured: after the first 3 months of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2020
- Study start14 Aug 2020
- Primary completion30 Aug 2022 (estimated)
- Study completion15 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Cardiac Surgical ProceduresStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA Intraoperative : We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure. post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery sternal stability and absence of dehiscence will be primary out come measure Secondary end point : Severe form of sternal deheiscence After 3months: stability of sternum will be assessed By CT chest with 3D bone reconstruction and the value of bone density as aconfirmatory test
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dr. Hamdy Singab
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr. Hamdy Singab, Ain Shams University
- Investigators
- hamdy singab, PHD, Study director, faculty of medicine,ain shams unversity
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04639089
- Sponsor's protocol ID
- MD166/2020
- Status last verified
- Feb 2022
- First submitted
- 17 Nov 2020
- Last updated
- 15 Feb 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: planning to make IPD available to other researchers
Publications
Carlson NE, Roach RB Jr. Platelet-rich plasma: clinical applications in dentistry. J Am Dent Assoc. 2002 Oct;133(10):1383-6. doi: 10.14219/jada.archive.2002.0054.
PubMed 12403541Dhurat R, Sukesh M. Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective. J Cutan Aesthet Surg. 2014 Oct-Dec;7(4):189-97. doi: 10.4103/0974-2077.150734.
PubMed 25722595Kassolis JD, Rosen PS, Reynolds MA. Alveolar ridge and sinus augmentation utilizing platelet-rich plasma in combination with freeze-dried bone allograft: case series. J Periodontol. 2000 Oct;71(10):1654-61. doi: 10.1902/jop.2000.71.10.1654.
PubMed 11063400Liu Y, Kalen A, Risto O, Wahlstrom O. Fibroblast proliferation due to exposure to a platelet concentrate in vitro is pH dependent. Wound Repair Regen. 2002 Sep-Oct;10(5):336-40. doi: 10.1046/j.1524-475x.2002.10510.x.
PubMed 12406171Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jun;85(6):638-46. doi: 10.1016/s1079-2104(98)90029-4.
PubMed 9638695Dawood AS, Salem HA. Current clinical applications of platelet-rich plasma in various gynecological disorders: An appraisal of theory and practice. Clin Exp Reprod Med. 2018 Jun;45(2):67-74. doi: 10.5653/cerm.2018.45.2.67. Epub 2018 Jun 29.
PubMed 29984206Everts PA, Knape JT, Weibrich G, Schonberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006 Jun;38(2):174-87.
PubMed 16921694
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Platelet Rich Pasma on Strenal Healing Post Median Strenotomy in Patients Undergoing Open Heart Surgery
- ClinicalTrials.gov ID
- NCT04639089
- Acronym / sponsor ID
- MD166/2020
- Conditions
- Cardiac Surgical Procedures
- Keywords
- Cardiac Surgical Procedures
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Dr. Hamdy SingabUniversity, hospital or other
- Study start
- 14 Aug 2020 (actual)
- Primary completion
- 30 Aug 2022 (estimated)
- Study completion
- 15 Dec 2023 (estimated)
- First posted
- 20 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small volume of plasma.
Because it is an autogenous preparation, PRP is inherently safe and therefore free from concerns over transmissible diseases such as HIV and hepatitis.
Its power of regeneration already proved by orthopedics and dentists in their trials to regenerate cartilages .We will use it to know its ability to enhance healing of sternum in vulnerable patients to sternal dehiscence after open heart surgery .
Detailed description
- INTRODUCTION Successful healing of the sternum after open heart surgery is a complicated phenomenon because of the natural body ability often fails to efficiently repaired of the sternum in patients after open cardiac surgery (Everts 2006). Recent evidence based data suggested new modalities to increase the quality and accerelate sternal healing in high risk patients after open heart surgery vulnerable for early sternal dehiscence (Liu 2002) . PRP considers as an attractive alternative option in that manner. Marx and associates demonstrated the positive influence of PRP on bone regeneration and healing since 1998 (Marx 1998 ) . Autologous PRP carries minimal risk of infectious diseases transmission, immunologic reactions, and rejection. PRP with concentrations 4 to 5 folds of the normal average platelet (1,100,000 platelets/μl ) proved to have a remarkable increase in bone mineral density and regeneration . the market for PRP grows from $45 million in 2009 to more than $120 million by 2016 (Dawood 2018 ). Multiple factors affect the PRP efficacy in sternal bone healing and regeneration process. Platelet preparation before surgical application is an area of concern with PRP. For this issue, an appropriate anticoagulant must be used to prevent the early spontaneous activation of the platelets (Kassolis 2000 ). Several anticoagulants have been employed for PRP preparation including heparin, citrate, acid-citrate-dextrose solution A or anticoagulant citrate dextrose-A ,citrate-phos phate-dextrose ,citrate-theophylline-adenosine- dipyrimadole and ethylene diamine tetra- acetic acid moreover, several manual or automated systems have been designed for preparing PRP including clinical laboratory methods and kits (Carlson 2002). PRP produced by single- or double-step centrifugation technology via platelet-pheresis (autologous selective filtration )and the cell separators,However, these methods are rarely used nowadays, due to several factors including high cost, large volume of peripheral blood should be harvested from the patients, and potentially damage to the platelet (Dhurat 2014) . Commercially available PRP kits and devices differ in ease of use, one or two step centrifugation protocols, centrifugation speed, final PRP volume, platelet count and activation, platelet and growth factor concentrations, and final RBCs' and WBCs' count.Nevertheless, the cost of the commercial kits for PRP processing is still a challenge (Trebinjac 2020) .
- AIM/ OBJECTIVES : To study the Effect of platlet rich plasma on sternal healing post median sternotomy in Patients undergoing open heart surgery
- METHODOLOGY:
- Type of Study: prospective clinical trial propensity matched comparative study
- Study Setting: Patients refered to our Cardiothoracic department, Faculty of medicine, Ain Shams University and ain shams specialized hospital to perform open heart surgery who fulfill our inclusion charateria.
- Study Period: It will be performed between march 2020 and january2022
- Study Population:
- Inclusion Criteria: Patients with one of which
- patients will under go open heart surgery with BMI >30 or
- diabetic patients
- patients with history of chest wall radiotherapy exposure or
- bilateral internal mammary artery harvesting .
- age > 70 years old -Exclusion Criteria: <!-- -->
- patient with history of open heart surgery
- patients with preoperative HB level <11
- All emergency and urgency cardiothoracic surgery
- Sampling Method: prospective clinical trials propensity matched comparative study.
- Sample Size: 50 patients
- Ethical Considerations: All the patients will sign an informed consent for operation and for being involved in the research and follow up process .
- Study Tools: platlets rich plasma
- Preparation technique : ultra centrifuge technique
- Study Procedures:
Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA
Intraoperative :
We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.
post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery sternal stability and absence of dehiscence will be primary out come measure
Secondary end point :
Severe form of sternal deheiscence After 3months: stability of sternum will be assessed By CT chest with 3D bone reconstruction and the value of bone density as aconfirmatory test
- Statistical Analysis:using the arithmetic mean, standard deviation using hypothesis student's "t" tests for quantitative data analysis, while qualitative data (ordinal, categorical) will be analyzed using The chi-square test (x2) (Fisher's Exact Test). For all statistical comparisons, a P value of <0.05 will be considered significant and a P value of <0.01 will be considered highly significant.
- Statistical Package:Data will be statistically analyzed using statistical package of social science (SPSS)
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
- Model description
- Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA Intraoperative : We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure. post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery sternal stability and absence of dehiscence will be primary out come measure Secondary end point : Severe form of sternal deheiscence After 3months: stability of sternum will be assessed By CT chest with 3D bone reconstruction and the value of bone density as aconfirmatory test
| Arm | Type | Receives |
|---|---|---|
| We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure | Experimental | Drug: platlet rich plasma on sternal healing post median sternotomyWe will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure |
| We will apply 10cm saline on the sternal edge before sternal closure | Placebo comparator | Drug: platlet rich plasma on sternal healing post median sternotomyWe will apply 10cm saline on the sternal edge before sternal closure |
Who may qualify
- Ages
- 70 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
Key inclusion criteria (6 listed)
- Patients with one of which
Key exclusion criteria (1 listed)
- patient with history of open heart surgery 2- patients with preoperative HB level <11 3-All emergency and urgency cardiothoracic surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| platlet rich plasma on sternal healing post median sternotomyAlso: PRPPatient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA Intraoperative : We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure. post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery | Drug | We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure, We will apply 10cm saline on the sternal edge before sternal closure |
Primary outcome
sternal stability and absence of dehiscence
Time frame: after the first 3 months of surgery
Radiographic strenal healing score information was collected from 50 patients during clinical follow-up determined by CT chest 3D axial slices analysis at five locations ( manubrium, top of aortic arch, main pulmonary artery , aortic root and aortopulmonary window) using 5 - points quantitative scale 0:minimal healing 1. no signs of healing 2. mild healing 3. moderate healing 4. complete healing
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2022.
- Results publication: PubMed 12403541Carlson NE, Roach RB Jr. Platelet-rich plasma: clinical applications in dentistry. J Am Dent Assoc. 2002 Oct;133(10):1383-6. doi: 10.14219/jada.archive.2002.0054.
- Results publication: PubMed 25722595Dhurat R, Sukesh M. Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective. J Cutan Aesthet Surg. 2014 Oct-Dec;7(4):189-97. doi: 10.4103/0974-2077.150734.
- Results publication: PubMed 11063400Kassolis JD, Rosen PS, Reynolds MA. Alveolar ridge and sinus augmentation utilizing platelet-rich plasma in combination with freeze-dried bone allograft: case series. J Periodontol. 2000 Oct;71(10):1654-61. doi: 10.1902/jop.2000.71.10.1654.
- Results publication: PubMed 12406171Liu Y, Kalen A, Risto O, Wahlstrom O. Fibroblast proliferation due to exposure to a platelet concentrate in vitro is pH dependent. Wound Repair Regen. 2002 Sep-Oct;10(5):336-40. doi: 10.1046/j.1524-475x.2002.10510.x.
- Results publication: PubMed 9638695Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jun;85(6):638-46. doi: 10.1016/s1079-2104(98)90029-4.
- Results publication: PubMed 29984206Dawood AS, Salem HA. Current clinical applications of platelet-rich plasma in various gynecological disorders: An appraisal of theory and practice. Clin Exp Reprod Med. 2018 Jun;45(2):67-74. doi: 10.5653/cerm.2018.45.2.67. Epub 2018 Jun 29.
- Results publication: PubMed 16921694Everts PA, Knape JT, Weibrich G, Schonberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006 Jun;38(2):174-87.
- Individual participant dataSharing planned: Yes. planning to make IPD available to other researchers
Related trials for Cardiac Surgical Procedures
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
Recruiting
Change in Platelet Lipid Metabolism and Procoagulant Phenotype Induced by Cardiopulmonary Bypass. Impact on Postoperative Inflammatory Response and Bleeding Complications During Cardiac Surgery.
Cardiac Surgery, Cardiopulmonary Bypass
Not yet recruiting
Effect of Warm Footbath Combined With Relaxation Exercise on Pain and Anxiety During Chest Tube Removal After Cardiac Surgery
Chest Tube Removal
RecruitingObservational study
The Impact of Fast-Track Anesthesia on Postoperative Neurocognitive Function in Patients Undergoing Cardiac Surgery
Delirium - Postoperative, Cardiac Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
hamdy singab, PHD study director
faculty of medicine,ain shams unversity
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing platlet rich plasma on sternal healing post median sternotomy in people with Cardiac Surgical Procedures, run by Dr. Hamdy Singab at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact hamdy singab, PHD (+201001008859 ext. 11, hamdi_singab@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
sternal stability and absence of dehiscence (time frame: after the first 3 months of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04639089, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2022.